In a deliberate wager on the unknown, Research Ireland has directed €20 million toward 22 research projects that resist easy answers — work on cancer, infection, and sustainability pursued not because the path is clear, but because the destination matters. Spread across eight Irish institutions, these efforts reflect a conviction as old as science itself: that the most consequential discoveries often begin as questions no one yet knows how to answer. The Frontiers for the Future programme asks researchers to follow curiosity into uncertainty, trusting that some of what is found there will chan
Research Ireland backs 22 high-risk projects with €20m in health and sustainability push
Research aims to improve patient safety by preventing hospital-acquired infections and developing therapies for aggressive cancers including brain tumors and bone metastases.
intellectual risks and ideas that might not yet have a clear pathway
Mark
So Research Ireland is putting €20 million into 22 projects. That sounds like a lot of money spread very thin—less than a million per project on average. How much does a research project actually need to get somewhere?
Mimi
That's the right question. Some of these projects are early-stage exploratory work, so smaller grants make sense. But you're right that it's modest. The real value here is that it's unrestricted curiosity-driven funding, which is rare. Most research money comes with specific deliverables and timelines.
Luke
But we don't know what happens after this funding ends. Is this seed money meant to generate preliminary results that attract larger grants? Or is it meant to be sufficient to complete the research? The source doesn't say.
Mimi
Fair point. The framing suggests it's meant to let researchers take risks and explore ideas that might not have immediate applications. That usually means early-stage work.
Mark
The bone cancer project and the infection prevention project—those sound like they could directly help patients. How soon could those translate into actual treatments?
Mimi
The bone cancer work is about understanding mechanism—why metastatic disease causes bone loss. That's foundational. The infection prevention project is further along conceptually; antimicrobial coatings are a known approach, but applying them to medical devices in a way that works is still development work. Neither is a clinical trial tomorrow.
Luke
And we don't have timelines from the researchers themselves. We're inferring from the project descriptions. The source tells us what they're studying, not when they expect results.
Mark
What about the brain tumor project? Glioblastoma is incredibly aggressive.
Mimi
Yes. They're using pre-clinical models—so animal models and lab work—to understand how blood vessels respond to tumor growth. That's still several steps away from human treatment. But understanding the mechanism could open new therapeutic angles.
Luke
Again, no timeline. No statement from Professor Campbell about what success looks like or when they might move to clinical work. We know what they're doing, not what they expect to achieve.
Mark
So this is really about creating space for researchers to think deeply about hard problems.
Mimi
Exactly. That's what the CEO said—intellectual risk-taking. Not every project will succeed. Some will hit dead ends. But the bet is that some will generate insights that wouldn't emerge under more conventional, outcome-focused funding.
Luke
Which is a reasonable bet, but it's still a bet. We don't have evidence from this programme yet about what the payoff has been historically. This is the announcement of the funding, not a retrospective on what similar programmes have produced.
The Pulse
- Patients are contracting infections from the very hospital devices meant to heal them — a quiet crisis that one UCD team is now racing to address through novel antimicrobial coatings.
- Aggressive cancers spreading to bone are triggering severe skeletal deterioration in patients already fighting for their lives, and a University of Galway researcher is working to understand why.
- Glioblastoma, one of the deadliest brain tumours known, remains stubbornly resistant to treatment — a Trinity College Dublin team is using cutting-edge imaging and genetics to find a new way in.
- €20 million is being distributed not to safe, incremental science, but to high-risk projects that may hit dead ends — a deliberate institutional bet that breakthrough discovery requires permission to fail.
- Eight institutions from Atlantic Technological University to University of Limerick are receiving funds, signalling a national effort to build research capacity beyond traditional centres of gravity.
In a deliberate wager on the unknown, Research Ireland has directed €20 million toward 22 research projects that resist easy answers — work on cancer, infection, and sustainability pursued not because the path is clear, but because the destination matters. Spread across eight Irish institutions, these efforts reflect a conviction as old as science itself: that the most consequential discoveries often begin as questions no one yet knows how to answer. The Frontiers for the Future programme asks researchers to follow curiosity into uncertainty, trusting that some of what is found there will change lives.
Research Ireland has committed €20 million to 22 research projects chosen precisely because they are difficult — work at the edge of current knowledge, where outcomes are uncertain but the potential for genuine discovery is real. The funding reaches teams at eight Irish institutions, each pursuing questions that could reshape medicine or sustainability without yet knowing exactly how.
Three projects capture the ambition at stake. At UCD, Dr Joseph Byrne's team is developing antimicrobial coatings for medical devices — a response to the troubling reality that patients regularly acquire infections from the equipment used to treat them. At the University of Galway, Professor Laoise McNamara is investigating why cancers that spread to bone cause such devastating skeletal damage, hoping to find mechanisms that could guide new therapies. And at Trinity College Dublin, Professor Matthew Campbell is studying how blood vessels in the brain respond to glioblastoma tumour growth, using advanced imaging and genetic tools to open new avenues against one of the most lethal cancers in existence.
The programme funding these projects — Frontiers for the Future — is structured around curiosity rather than commercial certainty. There are no guaranteed timelines, no obvious endpoints. Research Ireland CEO Dr Diarmuid O'Brien described this tolerance for uncertainty as essential to a healthy research ecosystem, one that gives scientists room to take intellectual risks and follow ideas wherever they lead. Minister James Lawless echoed the ambition, noting the projects span everything from cancer therapies to circular economy innovation.
What sets this investment apart is its honesty about risk. These are not refinements of proven methods — they are bets on researchers and on questions, made in the belief that some of this work will eventually change how we understand disease and build a sustainable world. The €20 million is, in essence, a public commitment to the idea that science needs space to be wrong before it can be transformative.
Research Ireland has committed €20 million to fund 22 ambitious research projects that operate at the frontier of what's possible—work that carries real risk but promises genuine breakthrough potential. The money flows to teams across eight Irish institutions, each pursuing questions that don't yet have clear answers but could reshape how we understand disease and build a more sustainable world.
Three projects illustrate the scope of what's being backed. At University College Dublin, Dr Joseph Byrne's team is studying glycoconjugate metal complexes—essentially, how to engineer antimicrobial coatings and therapies that can be applied to medical devices to prevent infections acquired during hospital stays. The problem is concrete: patients enter hospitals for treatment and leave with infections contracted from the very equipment meant to help them. The approach is novel enough that it needs protection and resources to develop. At the University of Galway, Professor Laoise McNamara is investigating why cancers that metastasize to bone—including multiple myeloma and other aggressive forms—trigger such severe and damaging bone loss in patients. Understanding the mechanism could guide development of therapies that slow or prevent this deterioration, improving quality of life for people already living with cancer. Trinity College Dublin's Professor Matthew Campbell is taking on glioblastoma, one of the most lethal primary brain tumors. His team will use advanced imaging and genetic tools to study how blood vessels in the brain respond when tumors grow, working with pre-clinical models to develop new therapeutic approaches for a disease that remains extraordinarily difficult to treat.
The Frontiers for the Future programme, under which these projects are funded, is deliberately structured to support what Research Ireland calls curiosity-driven research—work that may not have an obvious commercial endpoint or a clear timeline to application, but that could fundamentally change scientific understanding. Minister James Lawless, TD, described the 22 projects as ambitious in both scope and scale, spanning from pioneering cancer therapies to advances in circular economy and sustainability.
Dr Diarmuid O'Brien, CEO of Research Ireland, framed the funding as essential to a healthy research ecosystem. "Curiosity-driven research funding is an essential part of a healthy, purposeful and forward-looking research ecosystem," he said, adding that the programme gives researchers permission to take intellectual risks and pursue ideas that might not yet have a clear pathway. The awardees are distributed across Atlantic Technological University, Dublin City University, Trinity College Dublin, Tyndall National Institute, University College Cork, University College Dublin, University of Galway, and the University of Limerick—a geographic spread that reflects a deliberate effort to support research capacity across the country.
What distinguishes this funding from more conventional research grants is its tolerance for uncertainty. These are not projects with proven methodologies seeking incremental improvement. They are bets on researchers and questions, made in the belief that some of this work will yield discoveries that reshape medicine and sustainability. The €20 million represents a commitment to the idea that breakthrough science requires space to fail, to explore dead ends, and to follow curiosity wherever it leads.
Notable Quotes
Curiosity-driven research funding is an essential part of a healthy, purposeful and forward-looking research ecosystem.— Dr Diarmuid O'Brien, CEO of Research Ireland
The 22 projects announced today are ambitious in both scope and scale, spanning areas from pioneering cancer therapies to advancing a more sustainable and circular economy.— Minister James Lawless, TD
Want the full story?
Read the original at Siliconrepublic.com ↗
Health & Medicine